NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Arrowhead Pharmaceuticals, Inc. ARWR
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$829.4M
▲ 23258.2% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-0.5%
Net margin · FY25
-0.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 829.4M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 0 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-0.5%
Return on equity, FY2025
ROE
Operating margin11.9%
Net margin-0.2%
Return on assets-0.1%
Each USD of equity lost 1 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+56.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+50.5%
+56.6%
+115.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years+32.6%
Change, 10 years+127.9%
The share count grew 33% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2025
Total assetsUSD 1.4B
EquityUSD 466.1M
CashUSD 226.5M
Current ratio4.86×
Equity funds 34% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.8
0.0
0.2
0.2
0.1
0.1
0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
0.1
−0.6
−0.2
−0.2
−0.1
−0.1
0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
0.1
−0.6
−0.2
−0.2
−0.1
−0.1
0.1
−0.1
−0.0
−0.1
·
−0.1
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.6
−0.2
−0.2
−0.1
−0.1
0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−0.5
−262.5
−61.3
−43.6
−32.4
−23.9
39.9
−61.5
−38.8
−79.4
−66.5
−60.4
−166.0
−185.3
−32.0
−76.9
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed